New Study: CBD for Anxiety Disorders in Breast Cancer Patients

A recent clinical study has investigated whether cannabidiol (CBD) can help alleviate anxiety in women with advanced breast cancer. The results provide interesting, albeit inconclusive, insights into the effects of CBD on cancer-related anxiety. This could represent a promising alternative to conventional medications, which often come with significant side effects.

Background of the Study

Anxiety disorders are widespread among cancer patients and can significantly impact their quality of life. One of the most common issues is so-called "scanxiety," the fear of imaging scans used to assess tumor progression. Many patients experience severe nervousness, sleep disturbances, and panic attacks in the days and hours leading up to these examinations.

Currently, benzodiazepines are the standard treatment for anxiety in oncology. However, these medications come with several drawbacks, including dependency potential, cognitive impairments, sedation, and interactions with other drugs. Therefore, there is an urgent need for alternative, better-tolerated treatment options. CBD has shown anxiolytic effects in previous studies outside oncology and could be a promising alternative.

Study Design and Methodology

The randomized, placebo-controlled, double-blind study was conducted at the renowned Dana-Farber Cancer Institute. The goal of the study was to examine the effects of a single dose of 400 mg CBD on anxiety levels in patients with advanced breast cancer. A total of 50 women participated, divided into two equal groups:

• One group received a single 400 mg dose of CBD.

• The other group received a taste-matched placebo.

The participants took the substance 48 hours before undergoing imaging scans (e.g., CT or PET scan) for tumor assessment. Anxiety levels were measured using the "Visual Analog Mood Scale" (VAMS), a validated tool for assessing mood changes. The scale evaluates various emotional states, including anxiety, sadness, confusion, and tension. Participants rated their anxiety levels immediately before ingestion and two to four hours afterward.

Study Results

The primary question of the study was whether the change in anxiety levels differed significantly between the groups. The results showed that the reduction in anxiety levels in the CBD group was greater, but not statistically significant:

• CBD Group: Anxiety levels decreased from an average VAMS score of 70.6 to 51.5 after ingestion.

• Placebo Group: Anxiety levels decreased from 73.0 to 58.0 after ingestion.

• Conclusion: While anxiety reduction was slightly more pronounced in the CBD group, the difference was not statistically significant.

However, it was observed that anxiety levels in the CBD group were significantly lower two to four hours after ingestion compared to the placebo group. This suggests that CBD may have potential anxiolytic effects that warrant further investigation.

Safety and Side Effects

A crucial aspect of the study was evaluating the safety of CBD. Compared to conventional anxiety medications, CBD is believed to have a better tolerance profile. The researchers observed no severe side effects (Grade 3 or 4):

• No serious adverse events were reported.

• Two participants in the CBD group reported mild to moderate side effects:

  • One experienced mild nausea.

  • Another reported moderate pain.

These findings confirm previous research indicating that CBD is well tolerated in therapeutic doses. However, long-term effects must be further investigated, particularly in oncology settings.

Conclusion and Practical Implications

Although the study did not achieve its primary goal of demonstrating a statistically significant reduction in anxiety compared to the placebo, the results provide important insights into the potential of CBD in treating cancer-related anxiety disorders. The significantly lower anxiety levels after CBD ingestion justify further research with larger sample sizes and longer observation periods.

For patients seeking alternatives to benzodiazepines, CBD could be an interesting option. Future studies should focus on the long-term effects of CBD on anxiety, optimal dosing, and possible combination therapies. Given its minimal side effects, CBD could serve as a meaningful complementary treatment option for cancer patients.

Recommended CBD Products on Cannadusa

• Vitadol Gold – Bio CBD Oil 10% (1.000mg) – 10ml - 54,90€
• CANNALINE CBD Hempoil - 17,50€
• CBD Hemp Tea with 4% 35g - 14,90€